NXL
Nexalin Technology, Inc. NASDAQ Listed Sep 16, 2022$4.81
+3.89%
vs $4.63
Mkt Cap $78.8M
52w Low $0.32
48.6% of range
52w High $9.56
50d MA $2.85
200d MA $1.09
P/E (TTM)
-0.3x
EV/EBITDA
—
P/B
21.0x
Debt/Equity
0.0x
ROE
-219.4%
P/FCF
-15.9x
RSI (14)
31.90
ATR (14)
$0.52
Beta
4.23
50d MA
$2.85
200d MA
$1.09
Avg Volume
32.9K
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. It also engages in the development of Generation 2, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiates, chronic pain, Alzheimer's disease, and dementia. The company was incorporated in 2021 and is headquartered in Houston, Texas.
CIK (SEC)
Phone
713 660 1100
1776 Yorktown · Houston, TX 77056 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25, 2026 | AMC | -0.12 | -0.13 | -8.3% | 0.40 | -3.0% | -5.1% | -3.1% | -3.1% | -1.3% | +1.8% | — |
| Nov 14, 2025 | AMC | -0.12 | -0.13 | -8.3% | 1.08 | +0.0% | +0.0% | -1.9% | -0.9% | -6.5% | +2.9% | — |
| Aug 6, 2025 | AMC | -0.10 | -0.10 | +0.0% | 0.99 | -3.0% | -5.8% | -3.4% | -1.1% | -1.2% | -4.7% | — |
| May 13, 2025 | AMC | -0.10 | -0.15 | -50.0% | 1.19 | +0.0% | +2.5% | +1.6% | +2.4% | +0.0% | -3.1% | — |
| Mar 14, 2025 | AMC | -0.12 | -0.28 | -133.3% | 2.15 | +9.8% | +10.2% | -7.2% | +11.4% | +1.2% | -4.0% | — |
| Nov 8, 2024 | AMC | -0.12 | -0.23 | -91.7% | 3.80 | +0.5% | -12.1% | +13.2% | +3.7% | +4.6% | +2.9% | — |
| Aug 8, 2024 | AMC | — | -0.17 | — | 0.91 | -3.0% | +4.5% | -2.9% | +4.3% | +2.5% | -0.4% | — |
| May 10, 2024 | AMC | — | -0.14 | — | 1.28 | -1.6% | -3.1% | +10.5% | -0.7% | -2.2% | -1.5% | — |
| Mar 27, 2024 | AMC | — | -0.10 | — | 0.78 | +11.5% | +79.5% | +35.7% | +51.1% | -16.4% | -10.4% | — |
| Nov 13, 2023 | AMC | — | -0.31 | — | 0.34 | +0.0% | -15.9% | +5.9% | -5.0% | +5.6% | +0.0% | — |
| Aug 10, 2023 | AMC | — | -0.11 | — | 0.64 | +4.9% | -0.6% | +3.8% | -7.7% | -0.5% | -2.5% | — |
| May 10, 2023 | AMC | — | -0.10 | — | 0.85 | +2.4% | -0.0% | +0.0% | +2.4% | -10.3% | -1.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 24 | Maxim Group | Upgrade | Hold → Buy | — | $2.38 | $2.43 | +2.1% | -1.7% | -7.7% | -3.2% | -1.4% | -7.3% |
| Dec 5 | Maxim Group | Downgrade | Buy → Hold | — | $4.15 | $4.11 | -1.0% | +0.5% | +4.6% | -0.2% | -8.5% | +6.0% |
No insider trades available.
8-K · 5.02
!!! Very High
Nexalin Technology, Inc. -- 8-K 5.02: Executive Change
Sep 2
8-K · 5.03
! Medium
Nexalin Technology, Inc. -- 8-K 5.03: Amendment to Articles / Bylaws
Aug 27
8-K · 1.01
! Medium
Nexalin Technology, Inc. -- 8-K 1.01: Financing / Debt Agreement
Aug 21
8-K · 1.01
! Medium
Nexalin Technology, Inc. -- 8-K 1.01: Equity Issuance
Aug 20
8-K
Nexalin Technology, Inc. -- 8-K Filing
Nexalin Technology faces a critical Nasdaq delisting hearing on September 1, 2026, where panelists will evaluate both bid price and stockholders' equity deficiencies determining the company's exchange listing status.
Aug 17
8-K
Nexalin Technology, Inc. -- 8-K Filing
Nexalin Technology held its Annual Meeting with no additional stockholder proposals requiring approval beyond standard matters.
Aug 11
8-K · 1.01
!! High
Nexalin Technology, Inc. -- 8-K 1.01: Material Agreement
Nexalin Technology signed a material agreement with Nutex HQ LLC, though the specific terms and financial impact remain undisclosed in this filing summary.
Jul 29
8-K
Nexalin Technology, Inc. -- 8-K Filing
Nexalin Technology faces delisting from Nasdaq but may appeal the determination to preserve its exchange listing and avoid potential investor access restrictions.
Jul 27
8-K · 5.03
! Medium
Nexalin Technology, Inc. -- 8-K 5.03: Amendment to Articles / Bylaws
Nexalin Technology changed its fiscal year end, which may affect the timing of future financial reporting, earnings announcements, and investor communications.
Jun 17
8-K · 8.01
!! High
Nexalin Technology, Inc. -- 8-K 8.01: Material Event / Announcement
Nexalin Technology issued a press release on May 19, 2026, announcing unspecified transactions, providing limited disclosure regarding the nature and potential investor impact of these developments.
May 19
8-K · 1.01
!! High
Nexalin Technology, Inc. -- 8-K 1.01: Material Agreement
Nexalin Technology entered a material agreement with Lindus Health Limited, though specific terms remain undisclosed in this initial filing notification.
Apr 22
8-K · 7.01
! Medium
Nexalin Technology, Inc. -- 8-K 7.01: Regulation FD Disclosure
Nexalin Technology partnered with Lindus Health to conduct a clinical study, potentially advancing its therapeutic technology toward regulatory approval and commercialization.
Feb 25
Institutional (13F) — Top 16
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Peak6 Llc | 240,210 | $79K | Reduced | Jun 2026 |
| 2 | Citadel Advisors Llc | 150,796 | $50K | New | Jun 2026 |
| 3 | Vanguard Capital Management Llc | 126,536 | $42K | — | Jun 2026 |
| 4 | Jane Street Group, Llc | 35,016 | $20K | Added | Dec 2025 |
| 5 | Northern Trust Corp | 24,100 | $8K | — | Mar 2026 |
| 6 | Kovack Advisors, Inc. | 22,325 | $8K | Reduced | Jun 2026 |
| 7 | Hrt Financial Lp | 23,453 | $8K | New | Mar 2026 |
| 8 | Ubs Group Ag | 22,189 | $8K | Added | Mar 2026 |
| 9 | Susquehanna International Group, Llp | 20,928 | $7K | Added | Mar 2026 |
| 10 | Elevation Advisory Partners Llc | 10,000 | $6K | New | Mar 2026 |
| 11 | Raymond James Financial Inc | 12,100 | $4K | New | Mar 2026 |
| 12 | Fmr Llc | 1,500 | $522 | Reduced | Mar 2026 |
| 13 | Citigroup Inc | 1,459 | $481 | New | Jun 2026 |
| 14 | Wells Fargo & Company/mn | 1,000 | $348 | New | Mar 2026 |
| 15 | Farther Finance Advisors, Llc | 1,000 | $330 | — | Jun 2026 |
| 16 | Federation Des Caisses Desjardins Du Quebec | 873 | $288 | New | Jun 2026 |
Mutual Funds / ETFs (N-PORT) — Top 9
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Old Westbury Small & Mid Cap Strategies Fund | 158,819 | $143K | Jul 2026 |
| 2 | Avantis International Equity ETF | 36,586 | $50K | Feb 2026 |
| 3 | Fidelity Extended Market Index Fund | 90,520 | $43K | Feb 2026 |
| 4 | Avantis International Small Cap Equity ETF | 18,498 | $25K | Feb 2026 |
| 5 | Avantis Responsible International Equity ETF | 12,858 | $17K | Feb 2026 |
| 6 | Fidelity Total Market Index Fund | 17,031 | $10K | May 2026 |
| 7 | Fidelity Series Total Market Index Fund | 16,612 | $10K | May 2026 |
| 8 | Fidelity Nasdaq Composite Index Fund | 3,846 | $2K | Feb 2026 |
| 9 | Blackstone Alternative Multi-Strategy Fund | -200 | $-66 | Jun 2026 |
Valuation
Market Cap
$78.8M
Enterprise Value
$75.1M
P/E (TTM)
-0.33x
Forward P/E
—
PEG Ratio
0.03x
P/B
21.04x
P/S
363.09x
P/FCF
-15.90x
EV/EBITDA
—
Shares Out
16.4M
Financials (TTM)
Revenue
$217K
Net Income
-$9.0M
EBITDA
-$9.0M
Free Cash Flow
-$5.0M
Op Cash Flow
-$5.0M
EPS Basic
$-0.50
EPS Diluted
$-14.40
EPS Forward
$-0.35
Gross Margin
-148.4%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$4.6M
Total Liab.
$887K
Total Equity
$3.7M
Cash
$3.7M
LT Debt
$0
Book Value/Sh
$0.23
Debt/Equity
0.00x
Current Ratio
4.85
Quick Ratio
4.70
Returns & Growth
ROE
-219.4%
ROA
-177.4%
ROIC
-223.9%
Rev Growth YoY
+78.8%
EPS Growth YoY
+39.8%
Price Returns
2W
-3.3%
1M
-53.5%
3M
-57.1%
6M
-62.0%
12M
-84.9%
Technicals
52W High
$9.56
52W Low
$0.32
50d MA
$2.85
200d MA
$1.09
RSI (14)
31.90
ATR (14)
$0.52
Beta
4.23
Avg Volume
33K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
4
Ex-Div Date
Mar 23, 2007
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 26, 2026 4:33pm
· Source: financialmodelingprep.com